BioAge Labs, Inc. (BIOA)
5.35
-0.07
(-1.29%)
USD |
NASDAQ |
Oct 15, 16:00
5.36
+0.01
(+0.19%)
After-Hours: 20:00
BioAge Labs Research and Development Expense (Quarterly) : 24.36M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 24.36M |
| March 31, 2026 | 20.41M |
| December 31, 2025 | 24.50M |
| September 30, 2025 | 18.51M |
| June 30, 2025 | 19.84M |
| March 31, 2025 | 11.11M |
| December 31, 2024 | 19.22M |
| Date | Value |
|---|---|
| September 30, 2024 | 20.02M |
| June 30, 2024 | 10.47M |
| March 31, 2024 | 9.321M |
| December 31, 2023 | 10.08M |
| September 30, 2023 | 6.532M |
| June 30, 2023 | 9.234M |
| March 31, 2023 | 8.038M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Neumora Therapeutics, Inc. | 29.28M |
| Alumis, Inc. | 84.46M |
| ANI Pharmaceuticals, Inc. | 14.75M |
| Corcept Therapeutics, Inc. | 53.89M |
| Veru, Inc. | 4.353M |